

Leonardo De Luca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6487862/publications.pdf>

Version: 2024-02-01

192
papers

8,492
citations

87888

38
h-index

48315

88
g-index

215
all docs

215
docs citations

215
times ranked

9716
citing authors

#	ARTICLE	IF	CITATIONS
1	Post-percutaneous coronary intervention angina: From physiopathological mechanisms to individualized treatment. <i>Cardiology Journal</i> , 2022, 29, 850-857.	1.2	4
2	Management of acute coronary syndromes in older adults. <i>European Heart Journal</i> , 2022, 43, 1542-1553.	2.2	24
3	One-year clinical outcome of patients with left ventricular thrombus after acute myocardial infarction discharged on triple or dual antithrombotic therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 410-416.	2.1	3
4	Impact of serum uric acid levels on cardiovascular events and quality of life in patients with chronic coronary syndromes: Insights from a contemporary, prospective, nationwide registry. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 393-401.	2.6	3
5	Impact of age, gender and heart failure on mortality trends after acute myocardial infarction in Italy. <i>International Journal of Cardiology</i> , 2022, 348, 147-151.	1.7	9
6	Antithrombotic Strategies in Patients with Atrial Fibrillation and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>Journal of Clinical Medicine</i> , 2022, 11, 512.	2.4	3
7	Prevalence and clinical impact of high platelet reactivity in patients with chronic kidney disease treated with percutaneous coronary intervention: An updated systematic review and meta-analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 1086-1094.	1.7	1
8	Could the PARIS Risk Scores Be Useful for the Choice of Triple versus Dual Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention?. <i>Cardiology</i> , 2022, 147, 133-136.	1.4	1
9	One-Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus-Eluting Stents in High Bleeding Risk Patients. <i>Journal of the American Heart Association</i> , 2022, 11, e023454.	3.7	7
10	COVID-19, Vaccines, and Thrombotic Events: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 948.	2.4	18
11	Incidence, Characteristics, and Management of Patients with Recurrent Myocardial Infarctions: Insights from the EYESHOT POST-MI. <i>Journal of Interventional Cardiology</i> , 2022, 2022, 1-8.	1.2	2
12	Clinical Impact and Prognostic Role of Triglyceride to High-Density Lipoprotein Cholesterol Ratio in Patients With Chronic Coronary Syndromes at Very High Risk: Insights From the START Study. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 874087.	2.4	3
13	Impact of eGFR rate on 1-year all-cause mortality in patients with stable coronary artery disease. <i>European Journal of Internal Medicine</i> , 2022, 101, 98-105.	2.2	2
14	Impact of myocardial revascularization on long-term outcomes in a nationwide cohort of first acute myocardial infarction survivors. <i>European Heart Journal Supplements</i> , 2022, 24, C225-C232.	0.1	0
15	ANMCO position paper on antithrombotic treatment of patients with atrial fibrillation undergoing intracoronary stenting and/or acute coronary syndromes. <i>European Heart Journal Supplements</i> , 2022, 24, C254-C271.	0.1	2
16	ANMCO position paper ~Appropriateness of prescribing direct oral anticoagulants in stroke and systemic thromboembolism prevention in adult patients with non-valvular atrial fibrillation~™. <i>European Heart Journal Supplements</i> , 2022, 24, C278-C288.	0.1	1
17	Prediction of All-Cause Mortality Following Percutaneous Coronary Intervention in Bifurcation Lesions Using Machine Learning Algorithms. <i>Journal of Personalized Medicine</i> , 2022, 12, 990.	2.5	2
18	Management of Oral Anticoagulation and Antiplatelet Therapy in Post-Myocardial Infarction Patients with Acute Ischemic Stroke with and without Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2022, 11, 3894.	2.4	1

#	ARTICLE	IF	CITATIONS
19	Unravelling the puzzle of antithrombotic therapies for complex percutaneous coronary intervention. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 352-359.	3.0	8
20	COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases: insights from the START registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 513-520.	4.0	6
21	Comparison of P2Y12 receptor inhibitors in patients with ST-elevation myocardial infarction in clinical practice: a propensity score analysis of five contemporary European registries. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 94-103.	3.0	13
22	Percutaneous coronary intervention of unprotected left main and bifurcation in octogenarians: Subanalysis from RAIN (veRy thin stents for patients with left mAIn or bifurcatioN in real life). <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 755-763.	1.7	0
23	Prevalence and Predictors of Out-of-Target LDL Cholesterol 1 to 3 Years After Myocardial Infarction. A Subanalysis From the EYESHOT Post-MI Registry. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 149-157.	2.0	9
24	Combinations of antithrombotic therapies prescribed after percutaneous coronary intervention in patients with acute coronary syndromes and atrial fibrillation: data from the nationwide MATADOR-PCI registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e45-e47.	3.0	4
25	Temporal Trends in Invasive Management and In-Hospital Mortality of Patients With Non-ST Elevation Acute Coronary Syndromes and Chronic Kidney Disease. <i>Angiology</i> , 2021, 72, 236-243.	1.8	6
26	Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). <i>European Journal of Internal Medicine</i> , 2021, 85, 1-13.	2.2	31
27	Bleeding risk prediction in elderly patients managed invasively for acute coronary syndromes: External validation of the PRECISE-DAPT and PARIS scores. <i>International Journal of Cardiology</i> , 2021, 328, 22-28.	1.7	14
28	Current management and prognosis of patients with recurrent myocardial infarction. <i>Reviews in Cardiovascular Medicine</i> , 2021, 22, 731.	1.4	3
29	Comparing the Prognostic Impact of Prediabetes with Diabetes in a Nationwide Cohort of Patients with Chronic Coronary Syndromes: An Analysis of the START Registry. <i>Cardiology</i> , 2021, 146, 547-555.	1.4	0
30	Antithrombotic Therapy in Patients with Coronary Artery Disease and Prior Stroke. <i>Journal of Clinical Medicine</i> , 2021, 10, 1923.	2.4	3
31	Oral Antiplatelet Therapy for Secondary Prevention of Non-Cardioembolic Ischemic Cerebrovascular Events. <i>Journal of Clinical Medicine</i> , 2021, 10, 1721.	2.4	2
32	Effectiveness of fondaparinux vs unfractionated heparin following percutaneous coronary intervention in survivors of out-of-hospital cardiac arrest due to acute myocardial infarction. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1563-1567.	1.9	1
33	Impact of history of depression on 1-year outcomes in patients with chronic coronary syndromes: An analysis of a contemporary, prospective, nationwide registry. <i>International Journal of Cardiology</i> , 2021, 331, 273-280.	1.7	3
34	Reply: Applicability of ISCHEMIA in real-world practice: where to START?. <i>EuroIntervention</i> , 2021, 17, e183-e184.	3.2	0
35	Post-discharge antithrombotic management and clinical outcomes of patients with new-onset or pre-existing atrial fibrillation and acute coronary syndromes undergoing coronary stenting: Follow-up data of the MATADOR-PCI study. <i>European Journal of Internal Medicine</i> , 2021, 88, 28-34.	2.2	7
36	Pre-treatment with dual antiplatelet therapy in non-ST-segment elevation acute coronary syndromes: landing from guidelines recommendations to real-world ground. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 442-444.	3.0	2

#	ARTICLE	IF	CITATIONS
37	Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives. Journal of the American Heart Association, 2021, 10, e022125.	3.7	31
38	Is percutaneous coronary intervention safe during uninterrupted direct oral anticoagulant therapy in patients with atrial fibrillation and acute coronary syndromes?. Open Heart, 2021, 8, e001677.	2.3	8
39	ANMCO POSITION PAPER: Timing of coronary angiography in non-ST-segment elevation acute coronary syndromes. European Heart Journal Supplements, 2021, 23, C196-C203.	0.1	1
40	Updated antithrombotic strategies to reduce the burden of cardiovascular recurrences in patients with chronic coronary syndrome. Biomedicine and Pharmacotherapy, 2021, 140, 111783.	5.6	0
41	Association of Sex with Outcome in Elderly Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. American Journal of Medicine, 2021, 134, 1135-1141.e1.	1.5	6
42	Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO). Journal of Clinical Medicine, 2021, 10, 4185.	2.4	11
43	Benefit of Extended Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients Treated with Drug Eluting Stents for Coronary Bifurcation Lesions (from the BIFURCAT Registry). American Journal of Cardiology, 2021, 156, 16-23.	1.6	8
44	Fondaparinux During Intra-Aortic Balloon Pump Counterpulsation in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention. Heart Lung and Circulation, 2021, 30, 1545-1551.	0.4	0
45	Risk stratification and secondary prevention post-myocardial infarction: insights from the EYESHOT Post-MI study. Journal of Cardiovascular Medicine, 2021, 22, 478-485.	1.5	4
46	Periprocedural Myocardial Injury in High-Risk Patients With NSTEMI Pretreated With Ticagrelor for Less or More Than 6 Hours Before PCI. Journal of Clinical Pharmacology, 2021, , .	2.0	1
47	Lack of implementation of guidelines recommendations for coronary revascularization in stable patients with complex disease is associated with high rates of incomplete revascularization. Heart and Vessels, 2020, 35, 30-37.	1.2	3
48	Safety and efficacy of polymer-free biolimus-eluting stents versus ultrathin stents in unprotected left main or coronary bifurcation: A propensity score analysis from the RAIN and CHANCE registries. Catheterization and Cardiovascular Interventions, 2020, 95, 522-529.	1.7	3
49	Fifteen-Year Trends of Cardiogenic Shock and Mortality in Patients with Diabetes and Acute Coronary Syndromes. American Journal of Medicine, 2020, 133, 331-339.e2.	1.5	9
50	Impact of structural features of very thin stents implanted in unprotected left main or coronary bifurcations on clinical outcomes. Catheterization and Cardiovascular Interventions, 2020, 96, 1-9.	1.7	15
51	Incidence of Adverse Events at 3 Months Versus at 12 Months After Dual Antiplatelet Therapy Cessation in Patients Treated With Thin Stents With Unprotected Left Main or Coronary Bifurcations. American Journal of Cardiology, 2020, 125, 491-499.	1.6	10
52	Antithrombotic strategies for patients with coronary and lower extremity peripheral artery diseases: a narrative review. Expert Review of Cardiovascular Therapy, 2020, 18, 881-889.	1.5	3
53	Characteristics and Outcome of Patients ≥75 Years of Age With Prior Coronary Artery Bypass Grafting Admitted for an Acute Coronary Syndrome. American Journal of Cardiology, 2020, 125, 1788-1793.	1.6	3
54	Comparison of bioresorbable vs durable polymer drug-eluting stents in unprotected left main (from) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.7	5

#	ARTICLE	IF	CITATIONS
55	The Combination of Oral Anticoagulant and Antiplatelet Therapies: Stay One Step Ahead. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 391-398.	2.0	6
56	Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registry. International Journal of Cardiology, 2020, 316, 229-235.	1.7	23
57	Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence. Cardiovascular Drugs and Therapy, 2020, 34, 723-735.	2.6	11
58	Impact of Kissing Balloon in Patients Treated With Ultrathin Stents for Left Main Lesions and Bifurcations. Circulation: Cardiovascular Interventions, 2020, 13, e008325.	3.9	39
59	Composite trends of cardiogenic shock complicating acute myocardial infarction. European Journal of Heart Failure, 2020, 22, 673-675.	7.1	5
60	One-year clinical events and management of patients with atrial fibrillation hospitalized in cardiology centers: Data from the BLITZ-AF study. European Journal of Internal Medicine, 2020, 74, 55-60.	2.2	7
61	Clinical characteristics, management and outcomes of patients with acute coronary syndrome and atrial fibrillation: real-world data from two nationwide registries in Italy. Journal of Cardiovascular Medicine, 2020, 21, 99-105.	1.5	6
62	Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries. Cardiovascular Therapeutics, 2020, 2020, 1-8.	2.5	7
63	Antithrombotic management of patients with acute coronary syndrome and atrial fibrillation undergoing coronary stenting: a prospective, observational, nationwide study. BMJ Open, 2020, 10, e041044.	1.9	11
64	Statins plus ezetimibe in the era of proprotein convertase subtilisin/ kexin type 9 inhibitors. Kardiologia Polska, 2020, 78, 850-860.	0.6	10
65	External applicability of the ISCHEMIA trial: an analysis of a prospective, nationwide registry of patients with stable coronary artery disease. EuroIntervention, 2020, 16, e966-e973.	3.2	24
66	Management of atrial fibrillation in the emergency room and in the cardiology ward: the BLITZ AF study. Europace, 2019, 21, 230-238.	1.7	27
67	How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-AMI Study. Clinical Cardiology, 2019, 42, 1113-1120.	1.8	5
68	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet, The, 2019, 394, 1169-1180.	13.7	155
69	Daily risk of adverse outcomes in patients undergoing complex lesions revascularization: A subgroup analysis from the RAIN-CARDIOGROUP VII study (veRy thin stents for patients with left main or Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.4	10
70	Impact of Final Kissing Balloon and of Imaging on Patients Treated on Unprotected Left Main Coronary Artery With Thin-Strut Stents (From the RAIN-CARDIOGROUP VII Study). American Journal of Cardiology, 2019, 123, 1610-1619.	1.6	20
71	High thrombotic risk increases adverse clinical events up to 5 years after acute myocardial infarction. A nationwide retrospective cohort study. Monaldi Archives for Chest Disease, 2019, 89, .	0.6	6
72	Trends in management and outcome of patients with non-ST elevation acute coronary syndromes and peripheral arterial disease. European Journal of Internal Medicine, 2019, 59, 70-76.	2.2	9

#	ARTICLE	IF	CITATIONS
73	Short term outcome following acute phase switch among P2Y12 inhibitors in patients presenting with acute coronary syndrome treated with PCI: A systematic review and meta-analysis including 22,500 patients from 14 studies. <i>IJC Heart and Vasculature</i> , 2019, 22, 39-45.	1.1	7
74	Clinical outcomes, pharmacological treatment, and quality of life of patients with stable coronary artery diseases managed by cardiologists: 1-year results of the START study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 5, 334-342.	4.0	14
75	Comparison of Reduced-Dose Prasugrel and Standard-Dose Clopidogrel in Elderly Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Revascularization. <i>Circulation</i> , 2018, 137, 2435-2445.	1.6	116
76	Is ticagrelor safe in octogenarian patients with non-ST elevation acute coronary syndromes?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 12-14.	3.0	11
77	Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. <i>European Heart Journal</i> , 2018, 39, e1-e33.	2.2	22
78	Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry. <i>Angiology</i> , 2018, 69, 795-802.	1.8	35
79	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Heart Journal</i> , 2018, 39, 213-260.	2.2	2,246
80	Current management and treatment of patients with stable coronary artery diseases presenting to cardiologists in different clinical contexts: A prospective, observational, nationwide study. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 43-53.	1.8	25
81	Procedural Characteristics for the Optimization of Dual Antiplatelet Therapy—Duration. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 2464-2466.	2.9	3
82	Prevalence and pharmacologic management of familial hypercholesterolemia in an unselected contemporary cohort of patients with stable coronary artery disease. <i>Clinical Cardiology</i> , 2018, 41, 1075-1083.	1.8	7
83	Temporal course of vascular healing and neoatherosclerosis after implantation of durable- or biodegradable-polymer drug-eluting stents. <i>European Heart Journal</i> , 2018, 39, 2448-2456.	2.2	44
84	Characteristics, treatment and quality of life of stable coronary artery disease patients with or without angina: Insights from the START study. <i>PLoS ONE</i> , 2018, 13, e0199770.	2.5	8
85	Contemporary management of patients referring to cardiologists one to three years from a myocardial infarction: The EYESHOT Post-MI study. <i>International Journal of Cardiology</i> , 2018, 273, 8-14.	1.7	18
86	Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease. <i>European Heart Journal Supplements</i> , 2018, 20, F1-F74.	0.1	25
87	Evolution of STEMI network in Italy. <i>Minerva Cardiology and Angiology</i> , 2018, 66, 392-399.	0.7	1
88	Diabetic patients with acute coronary syndromes in contemporary European registries: characteristics and outcomes. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 198-213.	3.0	18
89	Fate of Nonculprit Plaques in Patients With STEMI Undergoing Primary PCI Followed by Statin Therapy. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 827-829.	5.3	3
90	International Expert Consensus on Switching Platelet P2Y ₁₂ Receptor Inhibiting Therapies. <i>Circulation</i> , 2017, 136, 1955-1975.	1.6	293

#	ARTICLE	IF	CITATIONS
91	APpropriAteness of percutaneous Coronary interventions in patients with ischaemic HEart disease in Italy: the APACHE pilot study. <i>BMJ Open</i> , 2017, 7, e016909.	1.9	16
92	Patients with non-ST segment elevation acute coronary syndromes managed without coronary revascularization: A population needing treatment improvement. <i>International Journal of Cardiology</i> , 2017, 245, 35-42.	1.7	6
93	Recent trends in management and outcome of patients with acute coronary syndromes and atrial fibrillation. <i>International Journal of Cardiology</i> , 2017, 248, 369-375.	1.7	22
94	Antithrombotic strategies in the catheterization laboratory for patients with acute coronary syndromes undergoing percutaneous coronary interventions. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 580-589.	1.5	8
95	Dual Antiplatelet Therapy Duration in Conservatively Managed Patients with Acute Coronary Syndrome: Any News?. <i>American Journal of Medicine</i> , 2017, 130, e515.	1.5	1
96	PEGASUS study. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, e100-e104.	1.5	2
97	Clinical pathways and management of antithrombotic therapy in patients with acute coronary syndrome (ACS): a Consensus Document from the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Society of Emergency Medicine (SIMEU) and Italian Society of Interventional Cardiology (SICI-GISE). <i>European Heart Journal Supplements</i> , 2017, 19, D130-D150.	0.1	4
98	Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry. <i>EuroIntervention</i> , 2017, 13, 459-466.	3.2	83
99	Safety and Efficacy of Switching From Clopidogrel to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention. <i>Journal of Cardiovascular Pharmacology</i> , 2016, 67, 336-343.	1.9	3
100	Contemporary Trends and Age- and Sex-Specific Sex Differences in Management and Outcome for Patients With ST-Segment Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	67
101	Everolimus-Eluting Bioresorbable Vascular Scaffold System in the Treatment of Cardiac Allograft Vasculopathy: the CART (Cardiac Allograft Reparative Therapy) Prospective Multicenter Pilot Study. <i>Journal of Cardiovascular Translational Research</i> , 2016, 9, 40-48.	2.4	9
102	Prognostic role of N-terminal pro-brain natriuretic peptide in asymptomatic hypertensive and diabetic patients in primary care: impact of age and gender. <i>Clinical Research in Cardiology</i> , 2016, 105, 421-431.	3.3	17
103	Percutaneous Treatment of Coronary Bifurcation Lesions. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	6
104	Switching of platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Review of the literature and practical considerations. <i>American Heart Journal</i> , 2016, 176, 44-52.	2.7	23
105	Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 152-167.	3.0	50
106	P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 229-243.	3.0	46
107	Optical coherence tomography for characterization of cardiac allograft vasculopathy in late survivors of pediatric heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 74-79.	0.6	23
108	Temporal trends in the epidemiology, management, and outcome of patients with cardiogenic shock complicating acute coronary syndromes. <i>European Journal of Heart Failure</i> , 2015, 17, 1124-1132.	7.1	95

#	ARTICLE	IF	CITATIONS
109	Effectiveness of Pretreatment With Dual Oral Antiplatelet Therapy. American Journal of Cardiology, 2015, 116, 660-668.	1.6	7
110	Contemporary registries on P2Y12 inhibitors in patients with acute coronary syndromes in Europe: overview and methodological considerations: Table 1. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 232-244.	3.0	13
111	Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT Study. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 441-452.	1.0	81
112	Contemporary antithrombotic strategies in patients with acute coronary syndromes managed without revascularization: insights from the EYESHOT study. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 168-178.	3.0	22
113	Quality of bowel cleansing in hospitalized patients undergoing colonoscopy: A multicentre prospective regional study. Digestive and Liver Disease, 2015, 47, 669-674.	0.9	22
114	Is the use of risk scores an indicator of guideline adherence for patients with acute coronary syndromes? Insights from the EYESHOT Registry. International Journal of Cardiology, 2015, 187, 80-83.	1.7	3
115	A multidisciplinary consensus document on follow-up strategies for patients treated with percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2015, 85, E129-39.	1.7	6
116	One-year outcome from an all-comers population of patients with <scp>ST</scp>-segment elevation myocardial infarction treated with biolimus-eluting stent with biodegradable polymer. Catheterization and Cardiovascular Interventions, 2015, 85, 352-358.	1.7	4
117	A Network Meta-Analysis on Randomized Trials Focusing on the Preventive Effect of Statins on Contrast-Induced Nephropathy. BioMed Research International, 2014, 2014, 1-9.	1.9	20
118	A decade of changes in clinical characteristics and management of elderly patients with non-ST elevation myocardial infarction admitted in Italian cardiac care units. Open Heart, 2014, 1, e000148.	2.3	57
119	Coronary plaque composition assessed by intravascular ultrasound virtual histology: Association with long-term clinical outcomes after heart transplantation in young adult recipients. Catheterization and Cardiovascular Interventions, 2014, 83, 70-77.	1.7	8
120	Twenty year follow-up after successful percutaneous balloon mitral valvuloplasty in a large contemporary series of patients with mitral stenosis. International Journal of Cardiology, 2014, 177, 881-885.	1.7	50
121	Coronary risk in candidates for abdominal aortic aneurysm repair. Journal of Cardiovascular Medicine, 2014, 15, 817-821.	1.5	5
122	Randomized Comparison of Xience V and Multi-Link Vision Coronary Stents in the Same Multivessel Patient With Chronic Kidney Disease (RENAL-DES) Study. Circulation, 2014, 129, 1104-1112.	1.6	37
123	Mechanisms of Atherothrombosis and Vascular Response to Primary Percutaneous Coronary Intervention in Women Versus Men With Acute Myocardial Infarction. JACC: Cardiovascular Interventions, 2014, 7, 958-968.	2.9	89
124	Inotropic agents in advanced heart failure: Repetita iuvant?. International Journal of Cardiology, 2014, 176, 6-7.	1.7	4
125	A prospective registry on carotid artery revascularisation selected by consensus of a cardiovascular team. EuroIntervention, 2014, 9, 1294-1300.	3.2	0
126	Body mass index, gender, and clinical outcome among hypertensive and diabetic patients with stage A/B heart failure. Obesity, 2013, 21, E500-7.	3.0	6

#	ARTICLE	IF	CITATIONS
127	The History of Research on Coronary Stenting. , 2013, , 167-179.		0
128	Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel. Current Medical Research and Opinion, 2012, 28, 203-211.	1.9	6
129	High-density lipoprotein levels and risk of cardiovascular events. Journal of Cardiovascular Medicine, 2012, 13, 575-586.	1.5	22
130	Feasibility and safety of transradial approach and bivalirudin treatment in elderly patients undergoing early invasive strategy for ACS. Journal of Cardiovascular Medicine, 2012, 13, 351-352.	1.5	9
131	Interobserver agreement in contrast harmonic endoscopic ultrasound. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1063-1069.	2.8	31
132	Regional differences and Italian charter to expand the primary angioplasty service. EuroIntervention, 2012, 8, P80-P85.	3.2	3
133	Pre-hospital treatment of STEMI patients. A scientific statement of the Working Group Acute Cardiac Care of the European Society of Cardiology. Acute Cardiac Care, 2011, 13, 56-67.	0.2	45
134	Immunosuppressive Therapy with Oral Prednisone to Prevent Restenosis after PCI. A Multicenter Randomized Trial. American Journal of Medicine, 2011, 124, 434-443.	1.5	29
135	The Stent for Life project in Italy. Journal of Cardiovascular Medicine, 2011, 12, 850-855.	1.5	1
136	Long-term outcome of provisional side-branch stenting for the treatment of unprotected distal left main coronary artery disease. Catheterization and Cardiovascular Interventions, 2011, 77, 765-772.	1.7	5
137	Early and Long-Term Outcomes After Combined Percutaneous Revascularization in Patients With Carotid and Coronary Artery Stenoses. JACC: Cardiovascular Interventions, 2011, 4, 560-568.	2.9	20
138	Rationale and design of the Randomized comparison of XiEnce V and Multilink VisioN coronary stents in the same multivessel patient with chronic kidney disease (RENAL-DES) study. Journal of Cardiovascular Medicine, 2010, 11, 310-317.	1.5	8
139	Evaluation of Infarct-Related Coronary Artery Patency and Microcirculatory Function After Facilitated Percutaneous Primary Coronary Angioplasty. JACC: Cardiovascular Interventions, 2010, 3, 1284-1291.	2.9	29
140	Evaluation and management of special subgroups after primary percutaneous coronary intervention. American Heart Journal, 2010, 160, S22-S27.	2.7	11
141	Individual patient-data meta-analysis comparing clinical outcome in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention with or without prior thrombectomy. ATTEMPT study: A pooled Analysis of Trials on Thrombectomy in acute Myocardial infarction based on individual Patient data. Vascular Health and Risk Management, 2009, 5, 243.	2.3	16
142	The Role of N-terminal PRO-Brain Natriuretic Peptide and Echocardiography for Screening Asymptomatic Left Ventricular Dysfunction in a Population at High Risk for Heart Failure. The PROBE-HF Study. Journal of Cardiac Failure, 2009, 15, 377-384.	1.7	88
143	Acute Heart Failure Syndromes in Patients With Coronary Artery Disease. Journal of the American College of Cardiology, 2009, 53, 254-263.	2.8	124
144	Comparison between balloon angioplasty and additional coronary stent implantation for the treatment of drug-eluting stent restenosis: 18-month clinical outcomes. Journal of Cardiovascular Medicine, 2009, 10, 469-473.	1.5	11

#	ARTICLE	IF	CITATIONS
145	Clinical implications and management of bleeding events in patients with acute coronary syndromes. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 677-686.	1.5	7
146	A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) – study design and rationale. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 192-199.	1.5	5
147	Clinical impact of thrombectomy in acute ST-elevation myocardial infarction: an individual patient-data pooled analysis of 11 trials. <i>European Heart Journal</i> , 2009, 30, 2193-2203.	2.2	245
148	Long-term results of immunosuppressive oral prednisone after coronary angioplasty in non-diabetic patients with elevated C-reactive protein levels. <i>EuroIntervention</i> , 2009, 5, 250-254.	3.2	16
149	The effect of thrombectomy on myocardial blush in primary angioplasty: The randomized evaluation of thrombus aspiration by two thrombectomy devices in acute myocardial infarction (RETAMI) trial. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 71, 84-91.	1.7	38
150	Impact of abciximab on coronary restenosis in diabetic patients undergoing elective paclitaxel-eluting stent implantation. A prospective, randomized, placebo-controlled study. <i>Acute Cardiac Care</i> , 2008, 10, 93-99.	0.2	6
151	Overview of emerging pharmacologic agents for acute heart failure syndromes. <i>European Journal of Heart Failure</i> , 2008, 10, 201-213.	7.1	39
152	Head-to-Head Comparison of Sirolimus- and Paclitaxel-Eluting Stent in the Same Diabetic Patient With Multiple Coronary Artery Lesions: A prospective, randomized, multicenter study. <i>Diabetes Care</i> , 2008, 31, 15-19.	8.6	38
153	Modalities of treatment and 30-day outcomes of unselected patients older than 75 years with acute ST-elevation myocardial infarction: data from the BLITZ study. <i>Journal of Cardiovascular Medicine</i> , 2008, 9, 1045-1051.	1.5	5
154	Unusual treatment of coronary artery aneurysm. <i>Journal of Cardiovascular Medicine</i> , 2008, 9, 864-865.	1.5	0
155	Early pharmacological treatment of acute heart failure syndromes: A systematic review of clinical trials. <i>Acute Cardiac Care</i> , 2007, 9, 10-21.	0.2	7
156	Post-cardioversion transesophageal echocardiography (POSTEC) strategy with the use of enoxaparin for brief anticoagulation in atrial fibrillation patients: the multicenter POSTEC trial (a pilot study). <i>Journal of Cardiovascular Medicine</i> , 2007, 8, 1034-1042.	1.5	11
157	Frequency of naturally-occurring regulatory T cells is reduced in patients with ST-segment elevation myocardial infarction. <i>Thrombosis Research</i> , 2007, 120, 631-634.	1.7	46
158	New Monodimensional Transthoracic Echocardiographic Sign of Left Atrial Appendage Function. <i>Journal of the American Society of Echocardiography</i> , 2007, 20, 324-332.	2.8	12
159	Review of Current and Investigational Pharmacologic Agents for Acute Heart Failure Syndromes. <i>American Journal of Cardiology</i> , 2007, 99, S4-S23.	1.6	70
160	Acute heart failure syndromes: clinical scenarios and pathophysiologic targets for therapy. <i>Heart Failure Reviews</i> , 2007, 12, 97-104.	3.9	60
161	Hyponatremia in acute heart failure syndromes: A potential therapeutic target. <i>Current Heart Failure Reports</i> , 2007, 4, 207-213.	3.3	6
162	Effects of Levosimendan on Left Ventricular Diastolic Function After Primary Angioplasty for Acute Anterior Myocardial Infarction: A Doppler Echocardiographic Study. <i>Journal of the American Society of Echocardiography</i> , 2006, 19, 172-177.	2.8	36

#	ARTICLE	IF	CITATIONS
163	Evidence-based use of levosimendan in different clinical settings. <i>European Heart Journal</i> , 2006, 27, 1908-1920.	2.2	193
164	Congestion in Acute Heart Failure Syndromes: An Essential Target of Evaluation and Treatment. <i>American Journal of Medicine</i> , 2006, 119, S3-S10.	1.5	339
165	Early elevation of interleukin-1 β and interleukin-6 levels after bare or drug-eluting stent implantation in patients with stable angina. <i>Thrombosis Research</i> , 2006, 117, 659-664.	1.7	37
166	Proper use of glycoprotein IIb/IIIa inhibitors in patients with non-ST elevation acute coronary syndromes undergoing coronary angiography: frankly, my dear, I don't give a damn. <i>Journal of Cardiovascular Medicine</i> , 2006, 7, 166-168.	1.5	0
167	Rotational atherectomy in the distal left anterior descending coronary artery through an internal mammary artery graft. <i>Journal of Cardiovascular Medicine</i> , 2006, 7, 368-372.	1.5	3
168	Antithrombotic therapy in atrial fibrillation: beyond the AFFIRM study. <i>Journal of Cardiovascular Medicine</i> , 2006, 7, 505-513.	1.5	2
169	Pharmacological treatment of chronic heart failure. <i>Heart Failure Reviews</i> , 2006, 11, 109-123.	3.9	29
170	Comparison Between Sirolimus- and Paclitaxel-Eluting Stent in T-Cell Subsets Redistribution. <i>American Journal of Cardiology</i> , 2006, 97, 494-498.	1.6	6
171	Cardiac Hemodynamic and Coronary Angiographic Characteristics of Patients Being Evaluated for Liver Transplantation. <i>American Journal of Cardiology</i> , 2006, 98, 178-181.	1.6	188
172	Effects of Glucose-Insulin-Potassium Infusion on Myocardial Perfusion and Left Ventricular Remodeling in Patients Treated With Primary Angioplasty for ST-Elevation Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2006, 98, 1349-1353.	1.6	24
173	Navigating the Crossroads of Coronary Artery Disease and Heart Failure. <i>Circulation</i> , 2006, 114, 1202-1213.	1.6	320
174	Congestion in acute heart failure syndromes: importance of early recognition and treatment. <i>Reviews in Cardiovascular Medicine</i> , 2006, 7, 69-74.	1.4	6
175	Pathophysiologic Targets in the Early Phase of Acute Heart Failure Syndromes. <i>American Journal of Cardiology</i> , 2005, 96, 11-17.	1.6	255
176	Reassessment of Dobutamine, Dopamine, and Milrinone in the Management of Acute Heart Failure Syndromes. <i>American Journal of Cardiology</i> , 2005, 96, 47-58.	1.6	207
177	Neurohormonal Inhibition in Heart Failure: Insights from Recent Clinical Trials. <i>American Journal of Cardiology</i> , 2005, 96, 3-9.	1.6	217
178	Hyponatremia in Patients with Heart Failure. <i>American Journal of Cardiology</i> , 2005, 96, 19-23.	1.6	169
179	Overview of Vasopressin Receptor Antagonists in Heart Failure Resulting in Hospitalization. <i>American Journal of Cardiology</i> , 2005, 96, 24-33.	1.6	142
180	Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. <i>Intensive Care Medicine</i> , 2005, 31, 638-644.	8.2	332

#	ARTICLE	IF	CITATIONS
181	Pre- and post-cardioversion transesophageal echocardiography for brief anticoagulation therapy with enoxaparin in atrial fibrillation patients: a prospective study with a 1-year follow-up. International Journal of Cardiology, 2005, 102, 447-454.	1.7	23
182	Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction. American Heart Journal, 2005, 150, 563-568.	2.7	57
183	Effects of abciximab and preprocedural glycemic control in diabetic patients undergoing elective coronary stenting. American Heart Journal, 2005, 149, 1135.e11-1135.e18.	2.7	12
184	Congenital coronary artery anomaly simulating an acute aortic dissection. Heart, 2004, 90, e11-e11.	2.9	4
185	Relationship Between Hiatal Hernia and Inguinal Hernia. Digestive Diseases and Sciences, 2004, 49, 243-247.	2.3	11
186	Endoscopic dilation of benign colorectal anastomotic stricture after low anterior resection: a prospective comparison study of two balloon types. Gastrointestinal Endoscopy, 2004, 60, 347-350.	1.0	59
187	Comparison of treatment outcomes between biliary plastic stent placements with and without endoscopic sphincterotomy for inoperable malignant common bile duct obstruction. World Journal of Gastroenterology, 2004, 10, 1212.	3.3	48
188	Stress-rest myocardial perfusion SPECT for functional assessment of coronary arteries with anomalous origin or course. Journal of Nuclear Medicine, 2004, 45, 532-6.	5.0	20
189	Nonpharmacologic care of heart failure: counseling, dietary restriction, rehabilitation, treatment of sleep apnea, and ultrafiltration. American Journal of Cardiology, 2003, 91, 41-50.	1.6	70
190	Endoscopic treatment of pancreatobiliary malignancies. Critical Reviews in Oncology/Hematology, 2001, 37, 127-135.	4.4	25
191	EUS imaging of the arteria lusoria: Case series and review. Gastrointestinal Endoscopy, 2000, 52, 670-673.	1.0	54
192	Use of cangrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Study design and interim analysis of the ARCANGELO study. Clinical Cardiology, 0, , .	1.8	5